Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851266 | 1.00 | ADORA3 (0.52) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1847200 | 1.00 | ADORA3 (0.52) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1848613 | 0.93 | ALDH1A1 (0.50) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1848611 | 0.93 | ALDH1A1 (0.50) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1847187 | 0.93 | ALDH1A1 (0.50) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1847184 | 0.93 | ALDH1A1 (0.50) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1847191 | 0.93 | ALDH1A1 (0.50) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1849827 | 0.92 | ADORA2A (0.49) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1846481 | 0.91 | ADORA2A (0.48) | ADORA3ALDH1A1HTTACHEADORA2A | |
| SCHEMBL1850679 | 0.91 | ALDH1A1 (0.48) | ADORA3ALDH1A1HTTACHEADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | claimed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | claimed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | claimed |
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | disclosed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | disclosed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
| EP-2197860-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044250-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ALDH1A1 362/4885HTT 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.